Research and Markets: Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies and 25 Drug Profiles

Tags:  

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7ndsd4/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects.

---

---

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens RandD pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

Companies Involved in Therapeutics Development

Drug Profiles

For more information visit http://www.researchandmarkets.com/research/7ndsd4/smoking_cessation

Contacts

Research and MarketsLaura Wood, Senior Manager.press@researchandmarkets.comU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Central Nervous System

Research and MarketsLaura Wood, Senior Manager.press@researchandmarkets.comU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Central Nervous System